Objectives: Rheumatoid arthritis is an autoimmune inflammatory disorder associated with increased risk of infection. The aim of this study was to evaluate infections frequency in rheumatoid arthritis patients and to report the independent associated risk factors.
INTRODUCTION
Over the past 40 years, the frequency of infections in rheumatoid arthritis (RA) has been reported to be high. Through hospital based case series, it was known that RA was associated with increased susceptibility to infection tract [1] [2] [3] . It has been postulated that it may be related to or to the frequent use of corticosteroids and other immunomodulatory therapies [2] [3] [4] . In previously published literature, only few case-control series have been conducted to report the risk of infection in patients with RA. The results in these studies were conflicting as some showed no increased risk [5, 6] while others did . However, few studies evaluated the risk factors in rheumatoid arthritis ( ), leucopenia, comorbidities, and medication such as steroids, non-biologic diseasemodifying antirheumatic drugs (DMARDs) and biological therapy [9] [10] [11] [12] . The latest was at the Mayo Clinic which reported that glucocorticoids (GCs) use was associated with a dose-related increased risk [13] .
Based on our research, no previous study has been conducted in Saudi Arabia to determine the risk of infections in patients with RA. Thus, the aim of our work was to determine the frequency of infections in patients with RA and to report the independent associated risk factors.
SUBJECTS AND METHODS
Arabia, were retrospectively evaluated for the rate of
The study was approved by the Biomedical Ethical Research Committee of the Faculty of Medicine at King Abdulaziz University; June 2011, approval number 550-11. atients with RA n 200 were identi ed according to the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) classi cation criteria for RA; however, before 2010 they were identi ed according to the 1 American College of Rheumatology classi cation criteria for RA [14] . Exclusion criteria were age less than 14 years and evidence of minor upper respiratory tract infection, due to the low severity of these infections some patients may not have been able to report them, and therefore, these may not be in the charts.
By de nition, any patient with chronic arthritis less than 16 years to be diagnosed as Juvenile Idiopathic Arthritis (JIA), but as 14 is the age limit for adults in many Arab countries they were included.
The following demographic features were obtained from the charts: age, gender, and duration of the disease at the time of the study (in years). The patients' treatments were reviewed. These included the use of the following: Glucocorticoids (GC), DMARDs namely Methotrexate (MT ), ulfasalazine, Le unomide, and antimalarial agents (Hydroxychloroquine [HCQ] or Chloroquine) either alone or in combination with biologics (the newer type of drug treatment for RA).
Activity of the disease was chronicled at the infection if the score was > 5.1 [15] evaluated based on the predefined criteria [16] . Comorbid illnesses were recorded as follows: Diabetes mellitus (DM), defined according to the WHO as fasting plasma glucose ≥ [17] according to the World Health Organization-International Society of Hypertension Guidelines as a diastolic blood pressure > 90 mmHg, or if the patient is taking any antihypertensive substances cardiovascular disease (CVD): Ischemic heart disease, arrhythmias, congestive heart failure and peripheral infiltrates indicating lung fibrosis or bronchiectasis) and malignancy.
Infection in general was defined as the presence of positive results of microbiologic cultures or radiologic IV, antibiotics, or non-serious cases. The definitions for each infection type were as follows: Bacteremia/ septicemia, urine in the presence clinical symptoms or urosepsis or was diagnosed based on the presence of consolidation seen by chest radiography in the , confirmed either soft tissue infections included wound infections, abscesses, abdominal infections were included based on clinical findings such as acute cholecystitis, ascending cholangitis, suppurative appendicitis, and peritonitis. The category "other infections" included any episodes of gastroenteritis, sinusitis and tonsillitis that required hospitalization .
Statistical Analysis
was determined for quantitative data and frequency for Similar to our findings, other studies showed pneumonia, UTI and septicemia to be common in patients with RA [7] [8] [9] . It is well known that there is a link between [19] . It is well known that the disease itself, its treatment, or both could mediate infection in patients with RA. By logistic regression analysis, GCs was one of the predictors of infection in our RA patient cohort, a finding which had been previously reported [7, [20] [21] [22] . In the Mayo Clinic study, GCs was the main predictor for the increased risk of infection in patients with RA [7, 21] . A population-based study compared the frequency and severity of infections in RA patients with age-and gender-matched individuals without RA from the same community, showed in older of serious infection [21] . The authors found that the use of GC was time-and dose-dependent risk for hospitalization due to bacterial infection. Using GC in the first 90 days 
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S.M. Attar and A.A.A. Al Ghamdi represented the highest risk. With regard to the dose of GC, no increased risk of serious infection was detected with low dose use (< 5 mg per day), while high doses of steroids (20 mg or more per day) were associated with a 6-times [23] . Although a significant association between GC use and infection was observed dosage of GC was not possible to determine due to the retrospective nature of the patients (increasing the dose of steroids temporary whenever the disease was active).
DMARDs were another considerable predictor for infection in RA patients but not as high as the GCs. As demonstrated in the largest retrospective study that included 27,710 RA patients, GCs but not DMARDs were associated with an increased risk of infections (both mild and serious) [24] treated controls in a German study [25] .
The present study showed a no significant increase risk of infection in patients who used MTX or HCQ. Studies were conflicting regarding the risk of infection with MTX use in patients with RA as some showed an associated risk [12, 24] , while others did not [21] .
Regarding comorbid illnesses, in the Mayo cohort study, comorbid conditions were considered as a risk factor [7] . Cardiovascular disease was a significant risk factor for infection and it was twice as common in patients with RA as in the controls [26] . . This point should be considered in the future management of patients, which needs the cooperation between the rheumatologist and the internal medicine team, in reducing the infection rate for atherosclerotic risk factors (high blood pressure, hyperlipidemia, obesity, and DM) will help to improve [27] .
The current study has some limitations. Given the all infections as some data may have been lost despite our In addition, some patients would have their infections managed locally in the peripheral hospitals. However, according to our search, only one study was conducted et al., evaluated the incidence of septic arthritis in RA patients that was estimated to be 2.13
. But our work assessed the risk of It is in this light that we are conducting a study comparing the frequency of infection in RA patients on conventional DMARDs versus biologics.
CONCLUSION
This present study demonstrated that the rate of infection in patients with RA was high but lower than that reported in other studies. Associated comorbid illnesses and the use of steroids predisposed them to develop infections that may necessitate hospitalization. Although, clinicians are aware of the risks associated with steroid use in RA, more the steroids to the lowest possible doses and managing associated comorbid illnesses.
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